MYO Stock Forecast: Myomo, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Myomo, Inc. is $3. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 62 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Myomo, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (86): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MYO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MYO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Aug 2026 | Ascendiant Capital | Maintains | Buy | — |
| 8 June 2026 | Ascendiant Capital | Maintains | Buy | — |
| 21 Nov 2025 | Ascendiant Capital | Maintains | Buy | — |
| 22 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 12 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 June 2025 | Craig-Hallum | Maintains | Buy | — |
| 5 June 2025 | Ascendiant Capital | Maintains | Buy | — |
| 8 May 2025 | Craig-Hallum | Maintains | Buy | — |
| 17 Mar 2025 | Ascendiant Capital | Maintains | Buy | — |
| 12 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Mar 2025 | Craig-Hallum | Maintains | Buy | — |
| 13 Dec 2024 | Craig-Hallum | Maintains | Buy | — |
| 13 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | $7.50 |
| 12 Nov 2024 | Ascendiant Capital | Maintains | Buy | — |
| 19 Aug 2024 | Ascendiant Capital | Maintains | Buy | — |
| 12 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 July 2024 | Craig-Hallum | Initiates | Buy | — |
| 9 July 2024 | Lake Street | Maintains | Buy | — |
| 9 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Dec 2023 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MYO.
This page is one stock. Monday covers all of them.
MYO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MYO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Myomo, Inc. returned +12.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MYO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.7×
- Price / book
- 11.8×
- EV / EBITDA
- —
Cheaper than 72% of US stocks
Cheaper than 6% of US stocks
- Revenue growth (YoY)
- 22.2%
- Earnings growth (YoY)
- —
- Gross margin
- 72.1%
- Operating margin
- −21.8%
- Net margin
- −33.1%
Higher than 72% of US stocks
Higher than 84% of US stocks
Higher than 22% of US stocks
Higher than 13% of US stocks
- Return on equity
- −173.5%
- Return on assets
- −18.2%
- Dividend yield
- —
Higher than 8% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Myomo, Inc. has a market value of $32.5M and an enterprise value of $42.0M.
Revenue in the twelve months to 30 June 2026: $43.3M. The latest quarter grew 21.3% year on year.
Net income over the same four quarters: −$14.5M, a −33.5% net margin.
Diluted earnings per share, trailing twelve months: −$0.34.
Free cash flow in the twelve months to 30 June 2026: −$9.1M.
Myomo, Inc. employs 194 people — $223K of revenue per employee.
Data provided by Twelve Data
MYO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MYO’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Myomo, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MYO
What is the MYO stock price forecast for 2026-2027?
The median 12-month analyst price target for Myomo, Inc. is $3, with estimates ranging from $1.7 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MYO stock a buy right now?
Of the 5 analysts covering Myomo, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Myomo, Inc. 62 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MYO?
As at 21 Nov 2026, Myomo, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (86 of 100).
Will MYO stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $3, and Ticker Nerd's factor model ranks Myomo, Inc. 62 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MYO stock forecast for 2030?
No analyst covering Myomo, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MYO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.7 to $11 over the next 12 months.
How has MYO stock performed over the past year?
Myomo, Inc. returned +12.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Myomo, Inc. do?
Myomo Inc. is a medical robotics company that develops and markets myoelectric orthotic devices for people with neuromuscular disorders and upper-limb paralysis. Its flagship MyoPro product line is a powered arm brace designed to support weakened or paralyzed arms and hands by detecting the user’s own muscle signals through non-invasive sensors.
About Myomo, Inc.
Myomo Inc. is a medical robotics company that develops and markets myoelectric orthotic devices for people with neuromuscular disorders and upper-limb paralysis. Its flagship MyoPro product line is a powered arm brace designed to support weakened or paralyzed arms and hands by detecting the user’s own muscle signals through non-invasive sensors. The company serves patients recovering from or living with conditions such as stroke, spinal cord injury, brachial plexus injury, traumatic brain injury, ALS, and multiple sclerosis. Myomo Inc. sells its devices through orthotics and prosthetics providers, direct clinical and insurance-based channels, the Veterans Administration, and selected distributors in the United States and international markets. The company focuses on restoring upper-limb function, supporting daily activities, and improving mobility for individuals with neurological and muscular impairments.
CEO Mr. Paul R. Gudonis · 194 employees · United States · https://myomo.com